"BioCity’s SC0062 gains NMPA breakthrough therapy designation" was originally created and published by Pharmaceutical ...

Albuminuria is a risk factor for cognitive decline in relatively young adults with diabetes and normal renal function, a new study suggests. In the study, diabetic patients with persistent ...

Albuminuria is a widely used biomarker for CKD prognosis and response to therapeutic interventions; however, there is large intra-individual day-to-day variability, up to 40%.

Despite the fact that albuminuria represents a key risk factor for chronic kidney disease (CKD), even in the absence of reduced filtration, testing for the condition is low among adult patients ...

BioCity Biopharma ("BioCity") announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD ...

BOSTON — Finerenone reduces CV and renal events in patients with type 2 diabetes and chronic kidney disease, and albuminuria is a good screening tool to identify candidates, according to a speaker.

When the study drugs were discontinued, albuminuria returned to near baseline. Any adverse event (AE) occurred in 52% of the trial population, and serious AEs in 6.1% to 7.1% across arms.

Early albuminuria reduction with finerenone (Kerendia) drove protection against chronic kidney disease (CKD) progression in people with type 2 diabetes, according to a post-hoc mediation analysis.

Microcalcification activity was positively associated with the extent of albuminuria, and a trend remained after adjustment. Average myocardial flow reserve ...

An SGLT2 inhibitor combined with a nonsteroidal mineralocorticoid receptor antagonist quickly cut urinary albumin-to-creatinine ratio (UACR) in patients with albuminuria and both chronic kidney ...